Cargando…
Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer
The PI3K/AKT pathway is frequently altered in advanced human prostate cancer mainly through the loss of functional PTEN, and presents as potential target for personalized therapy. Our aim was to determine the therapeutic potential of the pan-AKT inhibitor, AZD5363, in PTEN-deficient prostate cancer....
Autores principales: | De Velasco, Marco A., Kura, Yurie, Yoshikawa, Kazuhiro, Nishio, Kazuto, Davies, Barry R., Uemura, Hirotsugu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941290/ https://www.ncbi.nlm.nih.gov/pubmed/26910118 http://dx.doi.org/10.18632/oncotarget.7557 |
Ejemplares similares
-
Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of Pten-Deficient Prostate Cancer
por: De Velasco, Marco A., et al.
Publicado: (2021) -
Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2015) -
Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer
por: De Velasco, Marco A., et al.
Publicado: (2014) -
Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway
por: De Velasco, Marco A., et al.
Publicado: (2012) -
Transcriptome Profiling and Metagenomic Analysis Help to Elucidate Interactions in an Inflammation-Associated Cancer Mouse Model
por: Sakai, Kazuko, et al.
Publicado: (2021)